Cover Image
市場調查報告書

脂漏性皮膚炎:開發平台分析

Seborrhea - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 200996
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
脂漏性皮膚炎:開發平台分析 Seborrhea - Pipeline Review, H1 2017
出版日期: 2017年03月15日 內容資訊: 英文 39 Pages
簡介

脂漏性皮膚炎是主要作用於頭皮的一般性皮膚病,會發生脫屑和發癢,發炎,頭皮屑等症狀。發生在嬰兒身上則會特別稱之為新生兒頭部皮膚炎(乳痂)。脂漏性皮膚炎也會影響臉部和胸部、背部等人體各處皮脂腺。

本報告提供全球各國治療脂漏性皮膚炎所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查結果。

簡介

  • 分析範圍

脂漏性皮膚炎概要

治療藥的開發

  • 脂漏性皮膚炎開發中產品:概要
  • 脂漏性皮膚炎開發中產品:比較分析

各企業開發中的脂漏性皮膚炎治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

脂漏性皮膚炎治療藥:開發中的產品一覽(各企業)

脂漏性皮膚炎開發治療藥的企業

  • Aclaris Therapeutics, Inc.
  • Biomar Microbial Technologies
  • EpiPharm AG
  • Maruho
  • Phosphagenics Limited

脂漏性皮膚炎:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • Product-10156
  • Product-49778
  • lanoconazole
  • NCX-1047
  • 抑制痤瘡·脂漏性皮膚炎的SCD-1小分子
  • 脂肪漏性皮膚炎用醫藥品
  • IB-07-A-085
  • IB-07A081

脂漏性皮膚炎治療藥:最新的藥物簡介

脂漏性皮膚炎治療藥:開發暫停的產品

脂漏性皮膚炎治療藥:開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9070IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Seborrhea - Pipeline Review, H1 2017, provides an overview of the Seborrhea (Dermatology) pipeline landscape.

Seborrhea is form of skin eczema that mainly affects scalp, ears, face, chest, and folds of skin. Symptoms include skin flakes, red skin, itching and skin lesions. Risk factors include stress or fatigue, skin acne and obesity. Treatment includes antifungal medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Seborrhea - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Seborrhea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Seborrhea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Seborrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 2, 2 and 2 respectively.

Seborrhea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Seborrhea (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Seborrhea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Seborrhea (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Seborrhea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Seborrhea (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Seborrhea (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Seborrhea (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Seborrhea - Overview
  • Seborrhea - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Seborrhea - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Seborrhea - Companies Involved in Therapeutics Development
  • Aclaris Therapeutics Inc
  • Amorepacific Corp
  • Biomar Microbial Technologies
  • EpiPharm AG
  • Phosphagenics Ltd
  • Vyome Biosciences Pvt Ltd
  • Seborrhea - Drug Profiles
  • artemether - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • hydrogen peroxide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IB-07A081 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IB-07A085 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ketoconazole - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ketoconazole - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PAC-14028 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Seborrhea - Dormant Projects
  • Seborrhea - Discontinued Products
  • Seborrhea - Product Development Milestones
  • Featured News & Press Releases
  • Feb 27, 2017: Aclaris Therapeutics Submits New Drug Application for A-101 as a Novel Treatment for Seborrheic Keratosis - a Common Skin Condition
  • Nov 15, 2016: Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis, a Common Undertreated Skin Condition
  • Oct 19, 2016: New Observational Study Demonstrates Patient Impact of Seborrheic Keratosis, A Common, Undertreated Skin Condition Affecting 83.8 Million Americans
  • Jul 25, 2016: Aclaris Therapeutics Completes Enrollment of Phase 3 Pivotal Trials of A-101 for the Treatment of Seborrheic Keratosis; Provides Update on Clinical Programs
  • Jan 19, 2016: Aclaris Therapeutics Initiates Phase 3 Clinical Trials of A-101 for the Treatment of Seborrheic Keratosis
  • Mar 17, 2015: Aclaris Therapeutics' Lead Drug Candidate A-101 Achieves Statistically Significant Results in Third Phase 2 Clinical Trial for Seborrheic Keratosis, a Common Type of Benign Skin Tumor
  • Jan 27, 2015: Aclaris Therapeutics Announces Positive Results from Phase 2b Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Benign Skin Tumor
  • Jun 30, 2014: Aclaris Therapeutics Announces Positive Results from Phase 2 Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Skin Tumor
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Seborrhea, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Seborrhea - Pipeline by Aclaris Therapeutics Inc, H1 2017
  • Seborrhea - Pipeline by Amorepacific Corp, H1 2017
  • Seborrhea - Pipeline by Biomar Microbial Technologies, H1 2017
  • Seborrhea - Pipeline by EpiPharm AG, H1 2017
  • Seborrhea - Pipeline by Phosphagenics Ltd, H1 2017
  • Seborrhea - Pipeline by Vyome Biosciences Pvt Ltd, H1 2017
  • Seborrhea - Dormant Projects, H1 2017
  • Seborrhea - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Seborrhea, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top